8-K: Foghorn Therapeutics Presents Preclinical Data at AACR

Foghorn Therapeutics announced new preclinical data for its FHD-909 inhibitor and degrader programs targeting CBP, EP300, and ARID1B at the 2026 AACR Annual Meeting.

Summary

• Foghorn Therapeutics presented preclinical data at the 2026 American Association for Cancer Research (AACR) Annual Meeting for several of its programs.
• Data for the selective SMARCA2 inhibitor FHD-909 showed complete and durable tumor regression and induced anti-tumor immune memory when combined with an anti-PD-1 antibody in preclinical models.
• Preclinical data for the selective CBP degrader, FHT-171, demonstrated strong anti-tumor activity and a favorable tolerability profile in models of heavily pretreated ER+ breast cancer.
• The selective EP300 degrader program showed superior efficacy and safety compared to a clinical benchmark in preclinical multiple myeloma models.
• Progress was also reported for the selective ARID1B degrader program, with robust degradation achieved using cereblon-based degraders, indicating potential for oral bioavailability.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, with promising preclinical data across multiple programs, indicating continued progress and potential for future breakthroughs.

Positives

• FHD-909 in combination with an anti-PD-1 antibody demonstrated complete and durable tumor regression and induced anti-tumor immune memory in preclinical syngeneic mouse models.
• Selective CBP degrader FHT-171 showed strong anti-tumor activity and a favorable tolerability profile in preclinical models of heavily pretreated ER+ breast cancer.
• Selective EP300 degrader outperformed its clinical benchmark in preclinical multiple myeloma models, exhibiting enhanced safety and efficacy.
• Robust degradation was achieved with cereblon-based selective ARID1B degraders, showing potential for oral bioavailability.
• The company's Gene Traffic Control platform is systematically identifying and validating drug targets within the chromatin regulatory system.
• Foghorn's pipeline has the potential to address a significant number of patients with chromatin biology-implicated cancers.

Risks

• The company's business is subject to substantial risks and uncertainties, including those related to clinical trials and other factors detailed in its SEC filings.
• Actual results may differ materially from forward-looking statements due to inherent uncertainties, risks, and changes in circumstances.
• Macroeconomic and geopolitical circumstances could impact the company's and its collaborators' business operations, including research and development programs.
• Competition from other companies and industry developments could affect the company's progress.
• The availability of patients for clinical testing and the ability to obtain regulatory approval for product candidates are subject to risks.
• The company relies on CDMOs and CROs for manufacturing and research needs, which carries inherent risks.

Future Outlook

The company is advancing its pipeline of precision therapeutics, including the selective SMARCA2 inhibitor FHD-909 in Phase 1 trials, and preclinical assets like selective CBP, EP300, and ARID1B degraders towards INDs. The company anticipates continued progress in its research and development programs and potential expansion into new therapeutic areas.

Management Comments

• These exciting new preclinical data highlight FHD-909s potential in combination with an anti-PD-1 antibody in SMARCA4-mutated cancers.
• Additionally, our selective CBP degrader continues to show promise in ER+ breast cancer models and our selective EP300 degrader outperforms its clinical benchmark in preclinical multiple myeloma models.
• We also shared that we have achieved robust degradation with our cereblon-based selective ARID1B degraders, designed for potential oral bioavailability.
• We are pleased with the continued progress across our innovative pipeline which has the potential to provide meaningful benefit to patients.

Industry Context

StockSavvy.ai notes that Foghorn Therapeutics is operating in the highly competitive and innovative oncology drug development space, focusing on chromatin biology. Their strategy of developing precision therapeutics, particularly through targeted protein degradation, aligns with broader industry trends towards more personalized and effective cancer treatments. The collaboration with Lilly is a significant validation of their platform and approach.

Comparison to Industry Standards

• The preclinical data for FHD-909 in combination with anti-PD-1 antibodies shows complete and durable regression, suggesting potential to overcome resistance seen with standard therapies.
• The selective CBP degrader FHT-171 demonstrates strong anti-tumor activity in ER+ breast cancer models, comparable to or exceeding established treatments like Fulvestrant in certain aspects.
• The selective EP300 degrader shows superior efficacy and safety compared to the clinical benchmark inobrodib in multiple myeloma models, indicating a potential improvement over existing approaches.
• The company's approach to developing selective degraders for previously undruggable targets like ARID1B is a novel strategy within the industry.
• The development of long-acting injectable formulations, such as for FHT-171, is an industry trend aimed at improving patient compliance and therapeutic outcomes.

Stakeholder Impact

• Shareholders: Positive preclinical data may increase investor confidence and potentially impact stock valuation.
• Patients: Advances in novel cancer therapies offer hope for improved treatment outcomes for patients with difficult-to-treat cancers.
• Collaborators (e.g., Lilly): Continued progress on partnered programs like FHD-909 strengthens the collaboration and potential for future revenue.

Next Steps

• Advance preclinical assets (Selective SMARCA2, CBP, EP300, ARID1B degraders) towards INDs.
• Continue Phase 1 trial for FHD-909.
• Explore combinations for FHT-171 in ER+ breast cancer and other indications.
• Expand development of EP300 degrader into other hematological malignancies and AR+ prostate cancers.
• Further develop ARID1B degraders for ARID1A-mutant cancers.
• Continue to leverage the Gene Traffic Control platform for target identification and validation.

Key Dates

Recommendation

The preclinical data presented are promising and indicate strong pipeline development. However, without clinical trial results in humans, it is prudent to hold and await further data before making a stronger recommendation. The company's focus on novel targets and its collaboration with Lilly are positive factors.

Keywords

Foghorn Therapeutics, AACR, FHD-909, SMARCA2 inhibitor, CBP degrader, EP300 degrader, ARID1B degrader, Chromatin Biology